Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 1.00 |
| ▸ | ITGAV | P06756 | 20/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 15/20 | 1.00 |
| ▸ | ITGB5 | P18084 | 11/20 | 1.00 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4243657 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4242696 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL2929086 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL547592 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4238592 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| Hydrochloric Acid SCHEMBL2925351 | 0.99 | ITGB3 (0.99) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4243658 | 0.92 | ITGB3 (0.84) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL2925041 | 0.92 | ITGB3 (0.84) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4239337 | 0.92 | ITGB3 (0.84) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4245422 | 0.92 | ITGB3 (0.84) | ITGB3ITGAVITGA2BITGB5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637731-A1 | COMBINATION THERAPY FOR TREATING CANCER | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | claimed |
| WO-2024226533-A1 | METHODS FOR TREATING OCULAR DISORDERS WITH INTEGRIN ANTAGONIST COMPOSITION | CLEARSIDE BIOMEDICAL, INC. (US) | 2024-10-31 | — | — | WO | claimed |
| WO-2024137442-A1 | COMBINATION THERAPY FOR TREATING CANCER | GILEAD SCIENCES, INC. (US) | 2024-06-27 | — | — | WO | claimed |
| US-12497399-B2 | Fluorinated integrin antagonists | OCUTERRA THERAPEUTICS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4637731-A1 | COMBINATION THERAPY FOR TREATING CANCER | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250188457-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMA BY INHIBITION OF THE TFPI2-CD51-STAT6 SIGNALING AXIS | NORTHWESTERN UNIVERSITY | 2025-06-12 | — | — | US | disclosed |
| US-20250136987-A1 | CHANNEL MODULATORS | INFLAMMX THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4491184-A2 | CHANNEL MODULATORS | Auckland Uniservices Limited (NZ) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024226533-A1 | METHODS FOR TREATING OCULAR DISORDERS WITH INTEGRIN ANTAGONIST COMPOSITION | CLEARSIDE BIOMEDICAL, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| EP-3183346-B1 | CHANNEL MODULATORS | AUCKLAND UNISERVICES LTD (NZ) | 2024-10-23 | — | — | EP | disclosed |
| WO-2024137442-A1 | COMBINATION THERAPY FOR TREATING CANCER | GILEAD SCIENCES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240140942-A1 | FLUORINATED INTEGRIN ANTAGONISTS | FELIQS CORPORATION (JP) | 2024-05-02 | — | — | US | disclosed |
| US-20230279379-A1 | METHODS AND MICROFLUIDIC DEVICE FOR PRODUCING EXTRACELLULAR VESICLES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-09-07 | — | — | US | disclosed |
| US-11685737-B2 | Fluorinated integrin antagonists | OCUTERRA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230174980-A1 | CHANNEL MODULATORS | INFLAMMX THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230129394-A1 | METHODS OF TREATING OR PREVENTING VIRAL INFECTION WITH FLUORINATED AlphaV INTEGRIN ANTAGONISTS | FELIQS CORPORATION (JP) | 2023-04-27 | — | — | US | disclosed |
| US-11401516-B2 | Channel modulators | AUCKLAND UNISERVICES LIMITED (NZ) | 2022-08-02 | — | — | US | disclosed |
| CN-114010788-A | Channel modulators | 奥克兰联合服务有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685737-B2 | Fluorinated integrin antagonists | ITGB5, ITGB1, ITGA5 | ITGB3 5/4885ITGAV 7/4885ITGA2B 10/4885 |
| US-20230174980-A1 | CHANNEL MODULATORS | GJB2, GJA1, P2RX2 | ITGB3 1582/4885ITGAV 1339/4885ITGA2B 1176/4885 |
| US-20230129394-A1 | METHODS OF TREATING OR PREVENTING VIRAL INFECTION WITH FLUORINATED AlphaV INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGA1 | ITGB3 7/4885ITGAV 1/4885ITGA2B 8/4885 |
| US-20240140942-A1 | FLUORINATED INTEGRIN ANTAGONISTS | ITGB5, ITGB1, ITGA5 | ITGB3 5/4885ITGAV 7/4885ITGA2B 10/4885 |
| US-12497399-B2 | Fluorinated integrin antagonists | ITGB5, ITGB1, ITGA5 | ITGB3 5/4885ITGAV 7/4885ITGA2B 10/4885 |
| US-11401516-B2 | Channel modulators | GJB2, GJA1, P2RX2 | ITGB3 1582/4885ITGAV 1339/4885ITGA2B 1176/4885 |
| US-20250136987-A1 | CHANNEL MODULATORS | GJB2, GJA1, P2RX2 | ITGB3 1582/4885ITGAV 1339/4885ITGA2B 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.